Doxazosin

• Benign Prostatic Hyperplasia (BPH)
• Hypertension
• Lower Urinary Tract Symptoms
• Prostate Enlargement

Doxazosin (brand name Cardura) is a long-acting alpha-1 adrenergic receptor antagonist used to relieve the urinary symptoms of benign prostatic hyperplasia and as an add-on therapy for hypertension. Once a workhorse first-line antihypertensive, doxazosin's role in blood pressure management narrowed sharply after the ALLHAT trial, but it remains a useful second- or third-line agent and a staple in urology for men with prostate enlargement, particularly those who also need modest blood pressure lowering. Both immediate-release and extended-release formulations exist, and choosing between them depends on the indication, the patient's tolerance for orthostatic effects, and whether the drug is being used primarily for cardiovascular or urologic reasons.

Mechanism of Action

Doxazosin selectively blocks alpha-1 adrenergic receptors located on smooth muscle in arterioles, the bladder neck, the prostatic capsule, and the prostatic urethra. In the cardiovascular system, sympathetic nerve endings normally release norepinephrine, which binds alpha-1 receptors on vascular smooth muscle and triggers contraction. By competitively occupying these receptors, doxazosin allows the vessels to relax, lowering peripheral vascular resistance and thus blood pressure. Because the drug favors alpha-1 over alpha-2 receptors, it does not produce the reflex tachycardia seen with non-selective alpha blockers like phentolamine, although a modest heart-rate uptick can still occur in some patients.

In the lower urinary tract, alpha-1A and alpha-1D receptors dominate the dynamic, contractile portion of bladder outlet obstruction. When these receptors are blocked, the smooth muscle of the prostate, prostatic urethra, and bladder neck relaxes, widening the functional lumen through which urine must pass. Patients typically notice improved flow, reduced hesitancy, and less nocturia within one to two weeks. Doxazosin's relatively long elimination half-life, about 22 hours, supports once-daily dosing. The vasodilation that helps blood pressure can also produce orthostatic dizziness, especially after the first dose - the so-called first-dose phenomenon - which is why initiation always uses the lowest available strength taken at bedtime. Doxazosin is metabolized predominantly by hepatic CYP3A4, with negligible renal clearance, so dose reductions are not required for renal impairment but caution is needed in advanced liver disease. The drug also crosses into the iris and explains the intraoperative floppy iris syndrome that ophthalmologists encounter during cataract surgery in alpha-blocker users.

Clinical Use

For BPH, doxazosin sits alongside tamsulosin, alfuzosin, terazosin, and silodosin as effective alpha-blocker monotherapy. Compared with the more uroselective agents tamsulosin and silodosin, doxazosin is more likely to lower blood pressure and cause orthostatic symptoms but is less likely to cause abnormal ejaculation. Men who have both BPH and untreated mild hypertension may benefit from doxazosin as a single agent that addresses both problems. The American Urological Association considers all alpha-blockers comparably effective for moderate-to-severe lower urinary tract symptoms, with the choice driven by side-effect tolerance, comorbidities, and cost.

For hypertension, the ALLHAT trial showed doxazosin doubled the risk of heart failure compared with chlorthalidone, leading the American Heart Association and ACC to deprioritize alpha-blockers as initial therapy. Modern guidelines reserve doxazosin for resistant hypertension after thiazides, ACE inhibitors or ARBs, and calcium channel blockers have been optimized. It is also useful in older men with concurrent BPH who need an additional antihypertensive. Off-label, low-dose doxazosin or tamsulosin is sometimes added as medical expulsive therapy for distal ureteral stones; evidence is mixed but the strategy remains common in urology practice. Patients best suited to doxazosin tend to be older men with both blood pressure and prostate concerns who can tolerate orthostatic effects. For patients with severe hypertension or known heart failure, alternative agents are preferred. Patients with significant frailty, recurrent falls, or poorly controlled diabetes with autonomic neuropathy may experience disabling orthostasis on doxazosin and should be evaluated carefully before initiation. Lifestyle context for blood pressure control is reviewed in our article on understanding blood pressure numbers.

How to Take It

The immediate-release tablet is started at 1 mg taken at bedtime to minimize first-dose syncope, then doubled at one- to two-week intervals based on response and tolerance. Most BPH patients reach effective relief at 4 to 8 mg daily; the maximum is 8 mg for BPH and 16 mg for hypertension. The extended-release tablet, approved only for BPH, starts at 4 mg taken with breakfast and may be increased to 8 mg after three to four weeks. Extended-release tablets must be swallowed whole - never crushed, split, or chewed - because the controlled-release matrix may pass intact in stool, which is harmless.

If a dose is missed and remembered the same day, take it; if a full day is missed, skip and resume the next scheduled dose. Restarting after several missed doses requires going back to the starting dose to avoid recurrence of the first-dose hypotensive effect. Effects on flow and frequency emerge within days; full benefit takes two to four weeks. Store tablets at room temperature away from humidity. The first week often includes mild dizziness when standing - rising slowly from bed and from chairs reduces falls. Patients should avoid alcohol in large quantities, hot showers, and prolonged standing in hot weather during the first week, all of which can worsen orthostasis. If a planned surgical procedure is on the calendar, the prescriber should be informed; the drug is not typically held for routine surgery but is highly relevant for any cataract or glaucoma procedure.

Monitoring and Follow-Up

A baseline blood pressure, including a standing measurement to capture orthostatic drop, is recorded before initiation and at each dose increase. Significant orthostasis is defined as a fall of 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing, often accompanied by symptoms. The International Prostate Symptom Score (IPSS) provides a quantitative way to track BPH symptom response, ideally measured at baseline, at 4 to 6 weeks, and again at 3 months. A post-void residual ultrasound and PSA screen, when appropriate, are usually completed before starting alpha-blocker therapy.

No specific laboratory monitoring is required for ongoing safety. Annual basic metabolic panel and complete blood count are reasonable as part of general care. For older patients, a fall-risk assessment at each visit is essential because dizziness and orthostasis are leading drivers of fractures in men on alpha-blockers. Sudden recurrence of urinary retention, persistent symptomatic hypotension, or new ejaculatory dysfunction prompts dose review. Cataract surgery candidates must inform their ophthalmologist of doxazosin use because of intraoperative floppy iris syndrome risk; stopping the drug a few days before surgery does not reliably prevent it. Body weight and lower-extremity edema should be checked at each visit because alpha-blockers can produce mild fluid retention; significant edema or new shortness of breath should trigger evaluation for heart failure.

Special Populations

Elderly men, who form the bulk of doxazosin users, face the highest risk of orthostatic falls and require slow titration. No formal renal dose adjustment exists because the drug is hepatically metabolized, but reduced hepatic clearance in cirrhosis or severe hepatic impairment warrants caution and a lower starting dose. Doxazosin is rarely used in women, and not approved for pediatric BPH. Pregnancy data are limited; the drug is generally avoided during pregnancy unless clearly needed, and breastfeeding is not recommended given drug accumulation in milk in animal studies.

Patients on phosphodiesterase-5 inhibitors such as sildenafil or tadalafil should separate doses by at least four to six hours and use the lowest effective dose of each because additive hypotension can cause syncope. Strong CYP3A4 inhibitors such as ketoconazole, clarithromycin, or ritonavir can raise doxazosin exposure and amplify orthostasis. Concurrent use of other antihypertensives, particularly other alpha-blockers, beta-blockers, or volume-depleting diuretics, requires careful monitoring. Doxazosin does not meaningfully interact with warfarin or NSAIDs.

When to Contact Your Doctor

Call the office for fainting episodes, near-syncope on standing, or falls. Persistent dizziness, palpitations, chest pressure, or worsening shortness of breath - particularly with leg swelling or weight gain - should prompt evaluation for heart failure or hypotension. A painful erection lasting more than four hours is a urologic emergency. New or worsening urinary retention, hematuria, fevers, or back pain warrant a same-day call. Any planned cataract or glaucoma surgery should trigger a pre-operative discussion about temporarily stopping doxazosin. Allergic reactions including rash, swelling, or breathing difficulty require emergency care.

If you would like to review whether doxazosin makes sense for your prostate symptoms or blood pressure plan, contact us or schedule a visit with our team.